Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying super-enhancer-derived signatures with prognostic value through selective inhibitors (Microarray gene expression data)

ABSTRACT: Identifying super-enhancer-derived signatures with prognostic value through selective inhibitors (Microarray gene expression data)

PROVIDER: PRJNA1054542 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identifying super-enhancer-derived signatures with prognostic value through selective inhibitors (Microarray gene expression data)

Project description:CDK12 and CDK13 promote transcription elongation within the gene body and regulate the processivity of RNAPII. THZ531 inhibits the enzymatic activity of CDK12 and 13 through covalent binding. Gene expression profiling was performed to investigate the THZ531-induced transcription effect, and search the subset of sensitive genes in osteosarcoma cell lines, U2-OS and SJSA-1.

2024-01-31 | GSE250566 | GEO

Prognostic and diagnostic value of metal metabolism in colorectal cancer

Project description:Prognostic and diagnostic value of metal metabolism in colorectal cancer

| PRJNA1159221 | ENA

Rapid Acceleration of Diagnostics - Radical (RADx-rad): Identifying Biomarker Signatures of Prognostic Value for Multisystem Inflammatory Syndrome in Children (MIS-C)

Project description:Rapid Acceleration of Diagnostics - Radical (RADx-rad): Identifying Biomarker Signatures of Prognostic Value for Multisystem Inflammatory Syndrome in Children (MIS-C)

| PRJNA762387 | ENA

Rapid Acceleration of Diagnostics - Radical (RADx-rad): Identifying Biomarker Signatures of Prognostic Value for Multisystem Inflammatory Syndrome in Children (MIS-C)

Project description:Rapid Acceleration of Diagnostics - Radical (RADx-rad): Identifying Biomarker Signatures of Prognostic Value for Multisystem Inflammatory Syndrome in Children (MIS-C)

| PRJNA762389 | ENA

Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia

Project description:Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia

| PRJNA510364 | ENA

The diagnostic and prognostic value of hsa_circ_0084927 in colon adenocarcinoma and its ceRNA network construction (miRNA-Seq)

Project description:Object: This study aims to analyze the differentially expressed circRNA in colon adenocarcinoma (COAD) and evaluate its diagnostic and prognostic value. Establish a new prog

2021-12-06 | GSE189908 | GEO

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Project description:Chromatin regulators have become highly attractive targets for cancer therapy, yet many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. An important conundrum has thus emerged: how can inhibition of a general regulator of gene expression produce selective effects at specific oncogenes? Here we investigate how inhibition of the transcriptional coactivator BRD4 (Bromodomain containing 4) leads to selective inhibition of disease-critical oncogenes in a highly malignant blood cancer, multiple myeloma (MM). We found that BRD4 generally occupies the promoter elements of active genes together with the Mediator coactivator, but remarkably high levels of these two coactivator proteins were associated with a small set of exceptionally large enhancers. These super-enhancers are associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impact genes with super-enhancers, including the c-MYC oncogene. Super-enhancers were found at key oncogenic drivers in many other tumor cells. Thus, super-enhancers can regulate oncogenic drivers in tumor cells, which in some cells can be preferentially disrupted by BRD4 inhibition, which in turn contributes to the selective transcriptional effects observed at these oncogenes. These observations have implications for the discovery of novel cancer therapeutics directed at components of super-enhancers in diverse tumor types. ChIP-Seq for chromatin regulators and RNA Polymerase II in multiple myeloma, glioblastoma multiforme, and small cell lung cancer

2013-01-02 | E-GEOD-42355 | biostudies-arrayexpress

Opposing effects of estrogen and Runx2 on breast cancer cell proliferation: identification of a reciprocally-regulated gene signature with clinical prognostic value.

Project description:Analysis of reciprocal modulation of Runx2 and E2 signaling in BCA. Our objective was to investigate whether the interaction between estrogen and Runx2 signaling in breast cancer (BCa) could help refine an estrogen-responsive gene signature with improved prognostic value.

2012-03-06 | GSE30597 | GEO

Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

Project description:Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

| PRJNA453913 | ENA

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers [Affymetrix]

Project description:Chromatin regulators have become highly attractive targets for cancer therapy, yet many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. An important conundrum has thus emerged: how can inhibition of a general regulator of gene expression produce selective effects at specific oncogenes? Here we investigate how inhibition of the transcriptional coactivator BRD4 (Bromodomain containing 4) leads to selective inhibition of disease-critical oncogenes in a highly malignant blood cancer, multiple myeloma (MM). We found that BRD4 generally occupies the promoter elements of active genes together with the Mediator coactivator, but remarkably high levels of these two coactivator proteins were associated with a small set of exceptionally large enhancers. These super-enhancers are associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impact genes with super-enhancers, including the c-MYC oncogene. Super-enhancers were found at key oncogenic drivers in many other tumor cells. Thus, super-enhancers can regulate oncogenic drivers in tumor cells, which in some cells can be preferentially disrupted by BRD4 inhibition, which in turn contributes to the selective transcriptional effects observed at these oncogenes. These observations have implications for the discovery of novel cancer therapeutics directed at components of super-enhancers in diverse tumor types. Gene expression profiling in multiple myeloma cells after BET-Bromodomain inhibition with JQ1

2013-03-07 | E-GEOD-44929 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data